key: cord-0952891-olr0zk06 authors: Cutuli, Salvatore Lucio; De Maio, Flavio; De Pascale, Gennaro; Grieco, Domenico Luca; Monzo, Francesca Romana; Carelli, Simone; Tanzarella, Eloisa Sofia; Pintaudi, Gabriele; Piervincenzi, Edoardo; Cascarano, Laura; Xhemalaj, Rikardo; Sanguinetti, Maurizio; Posteraro, Brunella; Spanu, Teresa; Antonelli, Massimo title: COVID-19 influences lung microbiota dynamics and favors the emergence of rare infectious diseases: A case report of Hafnia Alvei pneumonia. date: 2021-04-18 journal: J Crit Care DOI: 10.1016/j.jcrc.2021.04.008 sha: 4df5ed282cbdc6379eae3995f9fd4b0b9996d619 doc_id: 952891 cord_uid: olr0zk06 The coronavirus disease 2019 causes a wide degree of organ dysfunction and is associated with bacterial secondary infection. We reported lung microbiota dynamics in a critically ill patient with coronavirus disease 2019, who developed severe Hafnia alvei ventilator-associated pneumonia and required extracorporeal membrane oxygenation support. The coronavirus disease 2019 (COVID-19) pandemic has been challenging patients, clinicians and healthcare systems worldwide [1] . Although mechanical ventilation (MV) represents a cornerstone of therapy for patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 [2] , such an intervention has been identified as a risk factor for ventilator-associated pneumonia (VAP) [3] . Specifically, COVID-19 may cause immune system dysfunction [4] and respiratory tract dysbiosis [5] , both fostering the development of secondary infections [6] . In the light of this view, we sought to report lung microbiota dynamics in a critically ill patient with COVID-19, who required MV and developed Hafnia alvei VAP [7] . The study was approved by the human research ethics committee of the Fondazione Policlinico A. Gemelli IRCCS (reference number: 1847). The patient provided specific signed permission for the publication. Hafnia alvei is a gram-negative bacterium that belongs to Enterobacteriaceae and has been rarely reported as a pathogen that causes respiratory tract infections, especially in immunocompromised patients [7] . Recently, Blonz et al [3] observed a significant incidence of VAP caused by Hafnia alvei (3.9% of respiratory isolates) in critically ill patients with COVID-19. In this study [3] , Enterobacteriaceae were isolated in 49.8% of respiratory samples, which may support the pathophysiological hypothesis of COVID-19 induced gut dysbiosis [8] and gut-lung crosstalk. Moreover, male sex represented a risk factor for the development of VAP, that may imply the influence of genetic and hormonal status on immune response. As a results, the emergence of rare infectious disease in critically ill patients with COVID-19 may be favored by concurrent genetic [3] , viral [4] and steroid [9] induced immune dysfunction, in a context of viral [8] and antibiotic induced multi-organ dysbiosis [10] . Our findings implicate that immune dysfunction fosters the development of rare and life-threatening bacterial infections. In this context, microbiota analysis represents a potential monitoring tool of dysbiosis, which may play a role in the prediction and early diagnosis of infectious disease [10] . Moreover, such analysis may provide important information on the effect of multiple interventions (e.g. pharmacological therapies, MV setting and nutrition) on microbiota balance, in order to orient clinical decision-making towards strategies that allow native microbiota preservation. This is the first report of Hafnia alvei infection and lung microbiota dysbiosis in a patient with COVID-19. Although our experience is restricted to one patient, Hafnia alvei infections and lung dysbiosis are rarely described in the literature and even a single, detailed, case scenario may be of interest when characterized by these important clinical implications. Hafnia alvei was rarely associated with pneumonia in critically ill patients before COVID-19 pandemic. Immune suppression and dysbiosis caused by both COVID-19 and consequent interventions may justify the emergence of rare pathogenic threats. In this context, microbiota J o u r n a l P r e -p r o o f analysis represents a potential monitoring tool in order to prevent and early diagnose infectious diseases. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19 Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study The genus Hafnia: from soup to nuts Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders Respiratory microbiome in mechanically ventilated patients: a narrative review Declarations of interest: None.